Ambros Therapeutics’ Path for Pain Drug Goes Through Reverse Merger With Werewolf
Along with Ambros Therapeutics’ merger with Werewolf Therapeutics, the combined company will raise $150 million in a private placement. Ambros is in Phase 3 testing with a drug developed for treating a type of pain that does not respond to currently available medicines, including opioids.